Blood test predicts which bladder cancer patients may safely skip surgery

Circulating tumor DNA, or ctDNA, can predict metastatic risk in patients who receive bladder-sparing treatment for muscle-invasive bladder cancer, but it is not a good predictor of local recurrence within the bladder, according to new data presented today by Fox Chase Cancer Center researchers.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup